Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3039-3047

  Ring, Brian Z ^b   Seitz, Robert S ^b   Beck, Rod ^b   Shasteen, William J ^b   Tarr, Shannon M ^b   Cheang, Maggie C U ^b   Yoder, Brian J ^b   Budd, G Thomas ^b   Nielsen, Torsten O ^b   Hicks, David G ^b   Estopinal, Noel C ^b   Ross, Douglas T ^a  

^a Applied Genomics Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; KI 67 ANTIGEN; PROTEIN P53; DIAGNOSTIC AGENT; ESTROGEN RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; ALGORITHM; BREAST TUMOR; COHORT ANALYSIS; EVALUATION; FEMALE; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ALGORITHMS; ANTIBODIES; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33746006844     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.6564     Document Type: Article

References (42)

1. Haybittle JL, Blamey RW, Elston CW, et al: A prognostic index in primary breast cancer. Br J Cancer 45:361-366, 1982
2. Galea MH, Blamey RW, Elston CE, et al: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207-219, 1992
3. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966-978, 2000
4. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
5. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
6. Mincey BA, Palmieri FM, Perez EA: Adjuvant therapy for breast cancer: Recommendations for management based on consensus review and recent clinical trials. Oncologist 7:246-250, 2002
7. Wood WC, Anderson M, Lyles RH, et al: Can we select which patients with small breast cancers should receive adjuvant chemotherapy? Ann Surg 235:859-862, 2002
8. Hayes DF, Isaacs C, Stearns V: Prognostic factors in breast cancer: Current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6:375-392, 2001
9. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
10. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
11. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
12. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
13. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
14. Chang HY, Sneddon JB, Alizadeh AA, et al: Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2:E7, 2004
15. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
16. Yoder BJ, Tso E, Skacel M, et al: The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 11:186-192, 2005
17. Makretsov NA, Huntsman DG, Nielsen TO, et al: Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10:6143-6151, 2004
18. Chen X, Cheung ST, So S, et al: Gene expression patterns in human liver cancers. Mol Biol Cell 13:1929-1939, 2002
19. Chen X, Leung SY, Yuen ST, et al: Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 14:3208-3215, 2003
20. Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 98:13784-13789, 2001
21. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
22. Pollack JR, Sorlie T, Perou CM, et al: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 99:12963-12968, 2002
23. Ross DT, Scherf U, Eisen MB, et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235, 2000
24. Schaner ME, Davidson B, Skrede M, et al: Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer 4:26, 2005
25. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
26. Whitfield ML, Sherlock G, Saldanha AJ, et al: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000, 2002
27. Elledge RM, McGuire WL: Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med 44:201-210, 1993
28. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690, 2001
29. Fisher B, Jeong JH, Dignam J, et al: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 30:62-66, 2001
30. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
31. Kido Y, Tamai I, Uchino H, et al: Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier. J Pharm Pharmacol 53:497-503, 2001
32. Boado RJ, Li JY, Nagaya M, et al: Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci U S A 96:12079-12084, 1999
33. Kanai Y, Segawa H, Miyamoto K, et al: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273: 23629-23632, 1998
34. Kim do K, Ahn SG, Park JC, et al: Expression of L-type amino acid transporter 1 (LAT1 ) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precursor lesions. Anticancer Res 24:1671-1675, 2004
35. Kobayashi H, Ishii Y, Takayama T: Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90:233-238, 2005
36. Chu TM, Nemoto T: Evaluation of carcinoembryonic antigen in human mammary carcinoma. J Natl Cancer Inst 51:1119-1122, 1973
37. Cangul H, Salnikow K, Yee H, et al: Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ Health Perspect 110:783-788, 2002 (suppl 5)
38. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
39. Dai H, van't Veer L, Lamb J, et al: A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65:4059-4066, 2005
40. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004
41. Nielsen TO, West RB, Linn SC, et al: Molecular characterisation of soft tissue tumours: A gene expression study. Lancet 359:1301-1307, 2002
42. Therneau TM, Atkinson EJ: An introduction to recursive partitioning using the RPART routine. Rochester, MN, Mayo Clinic, Technical Report, 1997